Aficamten-MYQORZO’s functions and effects

Aficamten (aficamten)-MYQORZO is a dedicated treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) The prescription drug, as a new allosteric reversible cardiac myosin inhibitor, relies on its precise targeting mechanism to effectively improve patients' cardiac pumping function, relieve clinical symptoms and improve exercise tolerance, making it a valuable targeted therapy option in the clinical treatment of obstructive hypertrophic cardiomyopathy.

Obstructive hypertrophic cardiomyopathy is characterized by abnormal thickening of myocardial tissue as its core pathological feature. The thickened myocardium directly squeezes the left ventricular cavity, hindering the smooth pumping of blood from the left ventricle and transporting it to all parts of the body, thereby causing typical symptoms such as shortness of breath, chest pain, and dizziness. Patients generally have obvious exercise intolerance and limited daily activities, which seriously affects the quality of life. If the condition is not well controlled, it will further increase the cardiac load.

Afkatai intervenes at the pathological core of the disease. Its mechanism of action is highly specific. By precisely combining with β-cardiac myosin in the myocardium, which is responsible for contractile function, it directly reduces the formation of excessive actin-myosin cross-bridges, inhibits the abnormally strong and prolonged contraction state of the myocardium from the root, effectively relieves the blood outflow obstruction of the left ventricle, and restores the contraction and relaxation of the heart to a more reasonable state, thus improving blood pumping efficiency and ensuring the blood supply throughout the body.

This medicine is convenient to take and comes in the form of oral tablets. Through precise regulation of myocardial contractile function, Afkaita can not only effectively relieve core clinical symptoms such as shortness of breath and chest pain in oHCM patients, but also significantly improve patients' exercise tolerance, help patients return to normal daily activities, and effectively improve patients' health status and life experience from the perspective of cardiac function.

Reference materials:https://www.drugs.com/myqorzo.html